Guardant Health, Inc.
Guardant Health, Inc. (GH) Stock Competitors & Peer Comparison
See (GH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GH | $61.40 | +0.20% | 7.7B | -18.33 | -$3.35 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.56% |
| TMO | $499.99 | +3.35% | 188.8B | 28.96 | $17.27 | +0.33% |
| DHR | $211.80 | +3.87% | 151.6B | 44.94 | $4.71 | +0.56% |
| IDXX | $645.55 | +1.97% | 51.6B | 53.66 | $12.03 | N/A |
| A | $121.63 | +3.82% | 34.6B | 29.96 | $4.06 | +0.81% |
| IQV | $191.15 | +3.11% | 32.5B | 27.74 | $6.89 | N/A |
| MTD | $1,321.45 | +3.40% | 27.2B | 33.54 | $39.37 | N/A |
| NTRA | $165.60 | +2.25% | 22.7B | -86.70 | -$1.91 | N/A |
| DGX | $180.23 | -1.90% | 20.2B | 21.59 | $8.35 | +1.72% |
Stock Comparison
GH vs DHR-PB Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, GH is priced at $61.40, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, GH's ROE is +2.19%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DHR-PB's competition here
GH vs TMO Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, TMO has a market cap of 188.8B. Regarding current trading prices, GH is priced at $61.40, while TMO trades at $499.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas TMO's P/E ratio is 28.96. In terms of profitability, GH's ROE is +2.19%, compared to TMO's ROE of +0.13%. Regarding short-term risk, GH is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check TMO's competition here
GH vs DHR Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, DHR has a market cap of 151.6B. Regarding current trading prices, GH is priced at $61.40, while DHR trades at $211.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas DHR's P/E ratio is 44.94. In terms of profitability, GH's ROE is +2.19%, compared to DHR's ROE of +0.07%. Regarding short-term risk, GH is less volatile compared to DHR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check DHR's competition here
GH vs IDXX Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, IDXX has a market cap of 51.6B. Regarding current trading prices, GH is priced at $61.40, while IDXX trades at $645.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas IDXX's P/E ratio is 53.66. In terms of profitability, GH's ROE is +2.19%, compared to IDXX's ROE of +0.64%. Regarding short-term risk, GH is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check IDXX's competition here
GH vs A Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, A has a market cap of 34.6B. Regarding current trading prices, GH is priced at $61.40, while A trades at $121.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas A's P/E ratio is 29.96. In terms of profitability, GH's ROE is +2.19%, compared to A's ROE of +0.19%. Regarding short-term risk, GH is less volatile compared to A. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check A's competition here
GH vs IQV Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, IQV has a market cap of 32.5B. Regarding current trading prices, GH is priced at $61.40, while IQV trades at $191.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas IQV's P/E ratio is 27.74. In terms of profitability, GH's ROE is +2.19%, compared to IQV's ROE of +0.20%. Regarding short-term risk, GH is less volatile compared to IQV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check IQV's competition here
GH vs MTD Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, MTD has a market cap of 27.2B. Regarding current trading prices, GH is priced at $61.40, while MTD trades at $1,321.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas MTD's P/E ratio is 33.54. In terms of profitability, GH's ROE is +2.19%, compared to MTD's ROE of -4.60%. Regarding short-term risk, GH is less volatile compared to MTD. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MTD's competition here
GH vs NTRA Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, NTRA has a market cap of 22.7B. Regarding current trading prices, GH is priced at $61.40, while NTRA trades at $165.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas NTRA's P/E ratio is -86.70. In terms of profitability, GH's ROE is +2.19%, compared to NTRA's ROE of -0.22%. Regarding short-term risk, GH is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check NTRA's competition here
GH vs DGX Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, DGX has a market cap of 20.2B. Regarding current trading prices, GH is priced at $61.40, while DGX trades at $180.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas DGX's P/E ratio is 21.59. In terms of profitability, GH's ROE is +2.19%, compared to DGX's ROE of +0.14%. Regarding short-term risk, GH is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DGX's competition here
GH vs WAT Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, WAT has a market cap of 18B. Regarding current trading prices, GH is priced at $61.40, while WAT trades at $302.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas WAT's P/E ratio is 27.25. In terms of profitability, GH's ROE is +2.19%, compared to WAT's ROE of +0.35%. Regarding short-term risk, GH is less volatile compared to WAT. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check WAT's competition here
GH vs ILMN Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, ILMN has a market cap of 15.6B. Regarding current trading prices, GH is priced at $61.40, while ILMN trades at $101.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas ILMN's P/E ratio is 12.89. In terms of profitability, GH's ROE is +2.19%, compared to ILMN's ROE of +0.53%. Regarding short-term risk, GH is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ILMN's competition here
GH vs PKI Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, GH is priced at $61.40, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas PKI's P/E ratio is 41.45. In terms of profitability, GH's ROE is +2.19%, compared to PKI's ROE of +0.04%. Regarding short-term risk, GH is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PKI's competition here
GH vs ICLR Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, ICLR has a market cap of 13.7B. Regarding current trading prices, GH is priced at $61.40, while ICLR trades at $175.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas ICLR's P/E ratio is 18.09. In terms of profitability, GH's ROE is +2.19%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, GH is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ICLR's competition here
GH vs TEM Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, TEM has a market cap of 13.6B. Regarding current trading prices, GH is priced at $61.40, while TEM trades at $80.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas TEM's P/E ratio is 37.45. In terms of profitability, GH's ROE is +2.19%, compared to TEM's ROE of -1.07%. Regarding short-term risk, GH is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check TEM's competition here
GH vs MEDP Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, MEDP has a market cap of 13B. Regarding current trading prices, GH is priced at $61.40, while MEDP trades at $463.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas MEDP's P/E ratio is 34.45. In terms of profitability, GH's ROE is +2.19%, compared to MEDP's ROE of +0.68%. Regarding short-term risk, GH is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check MEDP's competition here
GH vs RVTY Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, RVTY has a market cap of 10.9B. Regarding current trading prices, GH is priced at $61.40, while RVTY trades at $94.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas RVTY's P/E ratio is 40.91. In terms of profitability, GH's ROE is +2.19%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, GH is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check RVTY's competition here
GH vs QGEN Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, QGEN has a market cap of 10.8B. Regarding current trading prices, GH is priced at $61.40, while QGEN trades at $49.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas QGEN's P/E ratio is 29.09. In terms of profitability, GH's ROE is +2.19%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, GH is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check QGEN's competition here
GH vs EXAS Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, EXAS has a market cap of 9B. Regarding current trading prices, GH is priced at $61.40, while EXAS trades at $47.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas EXAS's P/E ratio is -8.71. In terms of profitability, GH's ROE is +2.19%, compared to EXAS's ROE of -0.38%. Regarding short-term risk, GH is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check EXAS's competition here
GH vs CRL Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, CRL has a market cap of 8B. Regarding current trading prices, GH is priced at $61.40, while CRL trades at $161.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas CRL's P/E ratio is -125.24. In terms of profitability, GH's ROE is +2.19%, compared to CRL's ROE of -0.02%. Regarding short-term risk, GH is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CRL's competition here
GH vs RDNT Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, RDNT has a market cap of 5.4B. Regarding current trading prices, GH is priced at $61.40, while RDNT trades at $70.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas RDNT's P/E ratio is -350.50. In terms of profitability, GH's ROE is +2.19%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, GH is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check RDNT's competition here
GH vs SHC Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, SHC has a market cap of 4.7B. Regarding current trading prices, GH is priced at $61.40, while SHC trades at $16.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas SHC's P/E ratio is 182.56. In terms of profitability, GH's ROE is +2.19%, compared to SHC's ROE of +0.05%. Regarding short-term risk, GH is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SHC's competition here
GH vs SYNH Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, GH is priced at $61.40, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas SYNH's P/E ratio is 61.40. In terms of profitability, GH's ROE is +2.19%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, GH is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check SYNH's competition here
GH vs OLK Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, GH is priced at $61.40, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas OLK's P/E ratio is -96.59. In terms of profitability, GH's ROE is +2.19%, compared to OLK's ROE of -0.07%. Regarding short-term risk, GH is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check OLK's competition here
GH vs TWST Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, TWST has a market cap of 1.7B. Regarding current trading prices, GH is priced at $61.40, while TWST trades at $28.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas TWST's P/E ratio is -19.85. In terms of profitability, GH's ROE is +2.19%, compared to TWST's ROE of -0.18%. Regarding short-term risk, GH is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check TWST's competition here
GH vs VIVO Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, GH is priced at $61.40, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas VIVO's P/E ratio is 21.09. In terms of profitability, GH's ROE is +2.19%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, GH is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check VIVO's competition here
GH vs GRAL Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, GRAL has a market cap of 1.2B. Regarding current trading prices, GH is priced at $61.40, while GRAL trades at $34.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas GRAL's P/E ratio is -2.92. In terms of profitability, GH's ROE is +2.19%, compared to GRAL's ROE of -0.18%. Regarding short-term risk, GH is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check GRAL's competition here
GH vs NEOG Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, NEOG has a market cap of 1.2B. Regarding current trading prices, GH is priced at $61.40, while NEOG trades at $5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas NEOG's P/E ratio is -1.12. In terms of profitability, GH's ROE is +2.19%, compared to NEOG's ROE of -0.41%. Regarding short-term risk, GH is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NEOG's competition here
GH vs OPK Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, GH is priced at $61.40, while OPK trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas OPK's P/E ratio is -5.42. In terms of profitability, GH's ROE is +2.19%, compared to OPK's ROE of -0.13%. Regarding short-term risk, GH is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check OPK's competition here
GH vs CDNA Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, CDNA has a market cap of 690.4M. Regarding current trading prices, GH is priced at $61.40, while CDNA trades at $12.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas CDNA's P/E ratio is 12.35. In terms of profitability, GH's ROE is +2.19%, compared to CDNA's ROE of +0.15%. Regarding short-term risk, GH is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CDNA's competition here
GH vs FLGT Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, FLGT has a market cap of 666.4M. Regarding current trading prices, GH is priced at $61.40, while FLGT trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas FLGT's P/E ratio is -13.11. In terms of profitability, GH's ROE is +2.19%, compared to FLGT's ROE of -0.05%. Regarding short-term risk, GH is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check FLGT's competition here
GH vs CSTL Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, CSTL has a market cap of 604.5M. Regarding current trading prices, GH is priced at $61.40, while CSTL trades at $20.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas CSTL's P/E ratio is -61.29. In terms of profitability, GH's ROE is +2.19%, compared to CSTL's ROE of -0.02%. Regarding short-term risk, GH is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CSTL's competition here
GH vs GRALV Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, GH is priced at $61.40, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas GRALV's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.19%, compared to GRALV's ROE of N/A. Regarding short-term risk, GH is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check GRALV's competition here
GH vs MYGN Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, MYGN has a market cap of 560.1M. Regarding current trading prices, GH is priced at $61.40, while MYGN trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas MYGN's P/E ratio is -1.40. In terms of profitability, GH's ROE is +2.19%, compared to MYGN's ROE of -0.63%. Regarding short-term risk, GH is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MYGN's competition here
GH vs LAB Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, LAB has a market cap of 485.1M. Regarding current trading prices, GH is priced at $61.40, while LAB trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas LAB's P/E ratio is -3.43. In terms of profitability, GH's ROE is +2.19%, compared to LAB's ROE of -0.26%. Regarding short-term risk, GH is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check LAB's competition here
GH vs PSNL Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, PSNL has a market cap of 428.3M. Regarding current trading prices, GH is priced at $61.40, while PSNL trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas PSNL's P/E ratio is -3.77. In terms of profitability, GH's ROE is +2.19%, compared to PSNL's ROE of -0.48%. Regarding short-term risk, GH is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check PSNL's competition here
GH vs CO Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, GH is priced at $61.40, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas CO's P/E ratio is 5.06. In terms of profitability, GH's ROE is +2.19%, compared to CO's ROE of +0.11%. Regarding short-term risk, GH is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CO's competition here
GH vs FLDM Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, GH is priced at $61.40, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas FLDM's P/E ratio is -4.74. In terms of profitability, GH's ROE is +2.19%, compared to FLDM's ROE of -0.51%. Regarding short-term risk, GH is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check FLDM's competition here
GH vs ATLN Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, ATLN has a market cap of 291.7M. Regarding current trading prices, GH is priced at $61.40, while ATLN trades at $4.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas ATLN's P/E ratio is -2.52. In terms of profitability, GH's ROE is +2.19%, compared to ATLN's ROE of +13.74%. Regarding short-term risk, GH is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ATLN's competition here
GH vs STIM Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, STIM has a market cap of 224.8M. Regarding current trading prices, GH is priced at $61.40, while STIM trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas STIM's P/E ratio is -2.96. In terms of profitability, GH's ROE is +2.19%, compared to STIM's ROE of -1.94%. Regarding short-term risk, GH is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check STIM's competition here
GH vs XGN Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, XGN has a market cap of 222.2M. Regarding current trading prices, GH is priced at $61.40, while XGN trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas XGN's P/E ratio is -11.35. In terms of profitability, GH's ROE is +2.19%, compared to XGN's ROE of -1.36%. Regarding short-term risk, GH is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check XGN's competition here
GH vs ACRS Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, ACRS has a market cap of 194.5M. Regarding current trading prices, GH is priced at $61.40, while ACRS trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas ACRS's P/E ratio is -1.14. In terms of profitability, GH's ROE is +2.19%, compared to ACRS's ROE of -0.96%. Regarding short-term risk, GH is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ACRS's competition here
GH vs NEO Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, NEO has a market cap of 168.3M. Regarding current trading prices, GH is priced at $61.40, while NEO trades at $6.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas NEO's P/E ratio is -8.05. In terms of profitability, GH's ROE is +2.19%, compared to NEO's ROE of -0.12%. Regarding short-term risk, GH is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NEO's competition here
GH vs MDXH Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, MDXH has a market cap of 162.8M. Regarding current trading prices, GH is priced at $61.40, while MDXH trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas MDXH's P/E ratio is -4.33. In terms of profitability, GH's ROE is +2.19%, compared to MDXH's ROE of -4.78%. Regarding short-term risk, GH is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MDXH's competition here
GH vs GTH Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, GH is priced at $61.40, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas GTH's P/E ratio is -1.11. In terms of profitability, GH's ROE is +2.19%, compared to GTH's ROE of -1.01%. Regarding short-term risk, GH is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check GTH's competition here
GH vs GENE Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, GH is priced at $61.40, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas GENE's P/E ratio is -38.25. In terms of profitability, GH's ROE is +2.19%, compared to GENE's ROE of -3.06%. Regarding short-term risk, GH is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check GENE's competition here
GH vs PRE Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, PRE has a market cap of 94.5M. Regarding current trading prices, GH is priced at $61.40, while PRE trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas PRE's P/E ratio is -1.90. In terms of profitability, GH's ROE is +2.19%, compared to PRE's ROE of -0.28%. Regarding short-term risk, GH is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check PRE's competition here
GH vs SERA Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, SERA has a market cap of 88.3M. Regarding current trading prices, GH is priced at $61.40, while SERA trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas SERA's P/E ratio is -2.80. In terms of profitability, GH's ROE is +2.19%, compared to SERA's ROE of -0.46%. Regarding short-term risk, GH is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SERA's competition here
GH vs PRENW Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, PRENW has a market cap of 83M. Regarding current trading prices, GH is priced at $61.40, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas PRENW's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.19%, compared to PRENW's ROE of -0.28%. Regarding short-term risk, GH is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check PRENW's competition here
GH vs VNRX Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, VNRX has a market cap of 73.9M. Regarding current trading prices, GH is priced at $61.40, while VNRX trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas VNRX's P/E ratio is -2.87. In terms of profitability, GH's ROE is +2.19%, compared to VNRX's ROE of +0.88%. Regarding short-term risk, GH is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check VNRX's competition here
GH vs BDSX Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, BDSX has a market cap of 66.1M. Regarding current trading prices, GH is priced at $61.40, while BDSX trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas BDSX's P/E ratio is -1.73. In terms of profitability, GH's ROE is +2.19%, compared to BDSX's ROE of -2.70%. Regarding short-term risk, GH is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BDSX's competition here
GH vs NOTV Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, NOTV has a market cap of 64.9M. Regarding current trading prices, GH is priced at $61.40, while NOTV trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas NOTV's P/E ratio is -0.72. In terms of profitability, GH's ROE is +2.19%, compared to NOTV's ROE of -0.49%. Regarding short-term risk, GH is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NOTV's competition here
GH vs STRRP Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, STRRP has a market cap of 30.5M. Regarding current trading prices, GH is priced at $61.40, while STRRP trades at $9.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas STRRP's P/E ratio is -4.74. In terms of profitability, GH's ROE is +2.19%, compared to STRRP's ROE of -0.04%. Regarding short-term risk, GH is less volatile compared to STRRP. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check STRRP's competition here
GH vs AKU Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, GH is priced at $61.40, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas AKU's P/E ratio is -0.13. In terms of profitability, GH's ROE is +2.19%, compared to AKU's ROE of -5.32%. Regarding short-term risk, GH is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check AKU's competition here
GH vs DRIO Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, DRIO has a market cap of 25.9M. Regarding current trading prices, GH is priced at $61.40, while DRIO trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas DRIO's P/E ratio is -0.85. In terms of profitability, GH's ROE is +2.19%, compared to DRIO's ROE of -0.58%. Regarding short-term risk, GH is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check DRIO's competition here
GH vs PRPO Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, PRPO has a market cap of 21.6M. Regarding current trading prices, GH is priced at $61.40, while PRPO trades at $14.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas PRPO's P/E ratio is -11.98. In terms of profitability, GH's ROE is +2.19%, compared to PRPO's ROE of -0.15%. Regarding short-term risk, GH is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PRPO's competition here
GH vs CEMI Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, GH is priced at $61.40, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas CEMI's P/E ratio is -0.63. In terms of profitability, GH's ROE is +2.19%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, GH is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check CEMI's competition here
GH vs ENZ Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, GH is priced at $61.40, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas ENZ's P/E ratio is -2.24. In terms of profitability, GH's ROE is +2.19%, compared to ENZ's ROE of -0.44%. Regarding short-term risk, GH is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ENZ's competition here
GH vs TRIB Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, TRIB has a market cap of 16.3M. Regarding current trading prices, GH is priced at $61.40, while TRIB trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas TRIB's P/E ratio is -0.87. In terms of profitability, GH's ROE is +2.19%, compared to TRIB's ROE of +1.12%. Regarding short-term risk, GH is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check TRIB's competition here
GH vs PMD Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, GH is priced at $61.40, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas PMD's P/E ratio is -5.24. In terms of profitability, GH's ROE is +2.19%, compared to PMD's ROE of -0.33%. Regarding short-term risk, GH is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check PMD's competition here
GH vs BNGO Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, BNGO has a market cap of 13.5M. Regarding current trading prices, GH is priced at $61.40, while BNGO trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas BNGO's P/E ratio is -0.09. In terms of profitability, GH's ROE is +2.19%, compared to BNGO's ROE of -1.67%. Regarding short-term risk, GH is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BNGO's competition here
GH vs ME Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, GH is priced at $61.40, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas ME's P/E ratio is -0.03. In terms of profitability, GH's ROE is +2.19%, compared to ME's ROE of -5.52%. Regarding short-term risk, GH is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ME's competition here
GH vs INBS Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, INBS has a market cap of 11M. Regarding current trading prices, GH is priced at $61.40, while INBS trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas INBS's P/E ratio is -0.74. In terms of profitability, GH's ROE is +2.19%, compared to INBS's ROE of -2.28%. Regarding short-term risk, GH is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check INBS's competition here
GH vs BGLC Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, BGLC has a market cap of 10.1M. Regarding current trading prices, GH is priced at $61.40, while BGLC trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas BGLC's P/E ratio is -3.43. In terms of profitability, GH's ROE is +2.19%, compared to BGLC's ROE of -0.36%. Regarding short-term risk, GH is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BGLC's competition here
GH vs BNR Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, BNR has a market cap of 9.6M. Regarding current trading prices, GH is priced at $61.40, while BNR trades at $9.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas BNR's P/E ratio is -2.87. In terms of profitability, GH's ROE is +2.19%, compared to BNR's ROE of -0.39%. Regarding short-term risk, GH is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BNR's competition here
GH vs CNTG Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, GH is priced at $61.40, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas CNTG's P/E ratio is -0.23. In terms of profitability, GH's ROE is +2.19%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, GH is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CNTG's competition here
GH vs ADVB Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, ADVB has a market cap of 9.1M. Regarding current trading prices, GH is priced at $61.40, while ADVB trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas ADVB's P/E ratio is -2.64. In terms of profitability, GH's ROE is +2.19%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, GH is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ADVB's competition here
GH vs MYNZ Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, MYNZ has a market cap of 8M. Regarding current trading prices, GH is priced at $61.40, while MYNZ trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas MYNZ's P/E ratio is -0.08. In terms of profitability, GH's ROE is +2.19%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, GH is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MYNZ's competition here
GH vs BIAF Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, BIAF has a market cap of 7.2M. Regarding current trading prices, GH is priced at $61.40, while BIAF trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas BIAF's P/E ratio is -0.44. In terms of profitability, GH's ROE is +2.19%, compared to BIAF's ROE of -9.30%. Regarding short-term risk, GH is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BIAF's competition here
GH vs STRR Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, STRR has a market cap of 6.9M. Regarding current trading prices, GH is priced at $61.40, while STRR trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas STRR's P/E ratio is -2.77. In terms of profitability, GH's ROE is +2.19%, compared to STRR's ROE of -0.04%. Regarding short-term risk, GH is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check STRR's competition here
GH vs BIAFW Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, BIAFW has a market cap of 5.6M. Regarding current trading prices, GH is priced at $61.40, while BIAFW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas BIAFW's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.19%, compared to BIAFW's ROE of -9.30%. Regarding short-term risk, GH is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check BIAFW's competition here
GH vs NVTA Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, GH is priced at $61.40, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas NVTA's P/E ratio is -0.00. In terms of profitability, GH's ROE is +2.19%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, GH is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NVTA's competition here
GH vs LMDXW Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, GH is priced at $61.40, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, GH's ROE is +2.19%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check LMDXW's competition here
GH vs LMDX Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, GH is priced at $61.40, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas LMDX's P/E ratio is -0.01. In terms of profitability, GH's ROE is +2.19%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, GH is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check LMDX's competition here
GH vs CHEK Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, CHEK has a market cap of 3.8M. Regarding current trading prices, GH is priced at $61.40, while CHEK trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas CHEK's P/E ratio is -0.30. In terms of profitability, GH's ROE is +2.19%, compared to CHEK's ROE of -0.37%. Regarding short-term risk, GH is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check CHEK's competition here
GH vs NDRA Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, NDRA has a market cap of 3.3M. Regarding current trading prices, GH is priced at $61.40, while NDRA trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas NDRA's P/E ratio is -0.07. In terms of profitability, GH's ROE is +2.19%, compared to NDRA's ROE of -2.83%. Regarding short-term risk, GH is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check NDRA's competition here
GH vs DMTK Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, GH is priced at $61.40, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas DMTK's P/E ratio is -0.04. In terms of profitability, GH's ROE is +2.19%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, GH is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check DMTK's competition here
GH vs ISPC Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, ISPC has a market cap of 3.3M. Regarding current trading prices, GH is priced at $61.40, while ISPC trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas ISPC's P/E ratio is -0.09. In terms of profitability, GH's ROE is +2.19%, compared to ISPC's ROE of -3.95%. Regarding short-term risk, GH is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check ISPC's competition here
GH vs AWH Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, GH is priced at $61.40, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas AWH's P/E ratio is -0.09. In terms of profitability, GH's ROE is +2.19%, compared to AWH's ROE of +4.83%. Regarding short-term risk, GH is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check AWH's competition here
GH vs SQL Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, GH is priced at $61.40, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas SQL's P/E ratio is -0.40. In terms of profitability, GH's ROE is +2.19%, compared to SQL's ROE of +10.28%. Regarding short-term risk, GH is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check SQL's competition here
GH vs APDN Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, APDN has a market cap of 1.8M. Regarding current trading prices, GH is priced at $61.40, while APDN trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas APDN's P/E ratio is -0.06. In terms of profitability, GH's ROE is +2.19%, compared to APDN's ROE of -3.75%. Regarding short-term risk, GH is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check APDN's competition here
GH vs HTGM Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, GH is priced at $61.40, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas HTGM's P/E ratio is -0.03. In terms of profitability, GH's ROE is +2.19%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, GH is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check HTGM's competition here
GH vs BIOC Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, GH is priced at $61.40, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas BIOC's P/E ratio is -0.01. In terms of profitability, GH's ROE is +2.19%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, GH is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check BIOC's competition here
GH vs TTOO Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, TTOO has a market cap of 336.5K. Regarding current trading prices, GH is priced at $61.40, while TTOO trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas TTOO's P/E ratio is -0.40. In terms of profitability, GH's ROE is +2.19%, compared to TTOO's ROE of +1.77%. Regarding short-term risk, GH is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check TTOO's competition here
GH vs SQLLW Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, SQLLW has a market cap of 116.2K. Regarding current trading prices, GH is priced at $61.40, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, GH's ROE is +2.19%, compared to SQLLW's ROE of +13.74%. Regarding short-term risk, GH is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check SQLLW's competition here
GH vs OPGN Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, OPGN has a market cap of 1K. Regarding current trading prices, GH is priced at $61.40, while OPGN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas OPGN's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.19%, compared to OPGN's ROE of -1.18%. Regarding short-term risk, GH is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check OPGN's competition here
GH vs DHR-PA Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, GH is priced at $61.40, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, GH's ROE is +2.19%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, GH is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check DHR-PA's competition here
GH vs MEUSW Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, GH is priced at $61.40, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas MEUSW's P/E ratio is N/A. In terms of profitability, GH's ROE is +2.19%, compared to MEUSW's ROE of -5.52%. Regarding short-term risk, GH is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for GH.Check MEUSW's competition here
GH vs OCDX Comparison August 2025
GH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GH stands at 7.7B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, GH is priced at $61.40, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GH currently has a P/E ratio of -18.33, whereas OCDX's P/E ratio is -42.28. In terms of profitability, GH's ROE is +2.19%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, GH is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for GH.Check OCDX's competition here